Navigation Links
MCG participating in national study to identify genetic variants in schizophrenia
Date:4/27/2009

AUGUSTA, Ga. The Medical College of Georgia is part of a large national study examining the genes of 10,000 patients with schizophrenia and 10,000 healthy individuals in an effort to pinpoint variations that can improve disease diagnosis and treatment.

Blood samples taken from each group will enable a sophisticated whole genome study to sort out genetic variations that convey individual risk for the disease that affects about 1 percent of the population. Schizophrenia's hallmark symptoms of hallucinations and the inability to manage basic functions, such as maintaining a job and/or personal relationships, typically arise early in adulthood.

"It's a devastating disease for which we have effective therapy but we have challenges as well," said Dr. Peter F. Buckley, a schizophrenia expert and chair of the Department of Psychiatry and Health Behavior in the MCG School of Medicine. "We hope this study moves us closer to unraveling the genetics of schizophrenia and, ultimately, that enables us to do a better job diagnosing and treating our patients."

While the study may not directly benefit participants, it enables a large-scale assessment of whether genetic variations that surfaced in a previous study of 3,391 individuals with schizophrenia and 3,181 controls continue to hold up and allow more detailed study of the variants, including their frequency, Dr. Buckley says.

The University of Southern California in Los Angeles led scientific teams that demonstrated some genes were missing and others over-expressed in three of the 23 chromosome pairs that comprise the human genome in a study published online in Nature July 30, 2008. The variations they found in chromosomes 22, 15 and 1 were rare but conveyed significant risk of schizophrenia. The Broad Institute, of Harvard Medical School and the Massachusetts Institute of Technology, performed the whole genome scans that enabled the findings. USC is coordinating the $10 million National Institute of Mental Health-funded follow up study which includes MCG.

MCG, which follows about 200 patients with schizophrenia, will enroll about 500 patients and 500 controls over the next five years as part of the study. A number of other mental health facilities in Georgia will help meet the enrollment target including:

  • Serenity Community Mental Health Center, which serves Richmond, Columbia, McDuffie, Wilkes, Warren and Taliaferro Counties
  • Ogeechee Behavioral Health Services, which serves Burke, Emanuel, Glascock, Jefferson, Jenkins and Screven Counties.
  • Northwest Georgia Regional Hospital in Rome, which serves 31 counties.
  • Highland Rivers Center in Dalton, which serves Bartow, Cherokee, Fannin, Floyd, Gilmer, Gordon, Murray, Paulding, Pickens, Polk and Whitfield Counties.

"We are grateful that the already busy staffs at these centers want to help in this quest to better understand this disease so that ultimately we can all do a better job for our patients," Dr. Buckley says.

Serenity and Ogeechee already were helping recruit for another MCG study to determine whether injectable medications versus pills can help with the significant problem of patients not taking their medication and relapsing. Dr. Thomas Muller, clinical director at the Rome hospital and former psychiatry residency director at MCG, as well as Dr. Ujwal Siddam Reddy, medical director at Highland Rivers Center and former chief resident in psychiatry at MCG, expressed interest in bringing research, including innovative therapies, to their part of the state as well.

Standardized checklists will ensure consistency in the patients and controls enrolled in the study. Also, the large number of enrollees at multiple sites will enable adequate representation from key ethnic and racial groups including whites, blacks and Latinos.

Anonymous blood samples drawn from participants also will be banked at an NIMH genetics repository at Rutgers University to contribute to the larger issue of understanding the genetics of mental illness. MCG will keep samples as well for a planned adjunct study on whether levels of brain-derived neurotrophic factor, a factor that helps optimize brain formation and function, provide clues about whether patients are headed toward relapse. MCG researchers began measuring factor levels in patients' blood last year to pursue the apparent correlation between a drop in the level and decreased responsiveness to drug treatment.

Other study sites include Cedars-Sinai Medical Center, Los Angeles; State University of New York Upstate, Syracuse; State University of New York at Stony Brook, Stony Brook; University of California, Los Angeles; University of North Carolina at Chapel Hill, Chapel Hill; and Wright State University, Dayton, Ohio.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Related medicine news :

1. New Dental Implant Research Study Open to Patients and Participating Dentists
2. MinuteClinic Becomes Participating Provider for Health Net Federal Services/TRICARE North, Insurer for Military Families
3. The Childrens Heart Foundation to Support National Congenital Heart Coalition (NCHC) on Capitol Hill by Participating in National Congenital Heart Lobby Day on February 10
4. MinuteClinic Becomes Participating Provider With Preferred Blue Network of BlueCross BlueShield of South Carolina
5. MinuteClinic Becomes Participating Provider With Horizon Blue Cross Blue Shield of New Jersey
6. MinuteClinic Becomes Participating Provider With Blue Cross and Blue Shield of Florida
7. 3 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques
8. El Camino Hospital Selects ITelagen for Multimillion-Dollar Electronic Medical Records (EMR) Initiative; Program Will Offer More Than 100 Participating Physicians State-of-the-Art Service and Support
9. Hospitals Participating in Get With The Guidelines(SM) Program Follow Heart Attack Treatment Guidelines Better Than Others
10. Participating in religion may make adolescents from certain races more depressed
11. New Website Portal Delivers Pre-Qualified Spinal Decompression Patients to Participating Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MCG participating in national study to identify genetic variants in schizophrenia
(Date:4/25/2017)... ... , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – ... but be heartened by the industry’s current surge. But another thing that unifies them ... At last they can simply, safely and effectively end their aroma anguish thanks ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place ... to a special report in the May issue of Consumer Reports focused on heart ... ranking for results achieved during and after coronary bypass and aortic valve replacement procedures. ...
(Date:4/24/2017)... FLORIDA (PRWEB) , ... April 24, 2017 , ... ... telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, ... LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet ...
(Date:4/24/2017)... ... April 24, 2017 , ... As part of the ... to honor the victims of the Holocaust and Nazi persecution, Center for Medicine ... and Auschwitz on its CMATH Champions trip to Germany and Poland next week. , ...
(Date:4/24/2017)... ... April 24, 2017 , ... The California Dental Association Foundation’s two-day volunteer dental ... 1,961 people during the April 22-23 event at the San Mateo Event Center. ... barriers to care, CDA Cares educates the public and policymakers about the importance of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... Calif. , April 19, 2017  SARES•REGIS ... buildings it is developing at Conejo Spectrum Business ... , to Atara Biotherapeutics, Inc. , a ... severe and life-threatening diseases that have been underserved ... allogeneic T-cell therapies for cancer, autoimmune and infectious ...
Breaking Medicine Technology: